Revenue Breakdown
Composition ()
No data
Revenue Streams
Biodesix Inc (BDSX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Lung Diagnostic Testing, accounting for 91.1% of total sales, equivalent to $19.84M. Another important revenue stream is Development Services. Understanding this composition is critical for investors evaluating how BDSX navigates market cycles within the Healthcare Facilities & Services industry.
Profitability & Margins
Evaluating the bottom line, Biodesix Inc maintains a gross margin of 81.14%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -32.36%, while the net margin is -40.04%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively BDSX converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, BDSX competes directly with industry leaders such as XGN and DCGO. With a market capitalization of $82.26M, it holds a significant position in the sector. When comparing efficiency, BDSX's gross margin of 81.14% stands against XGN's 58.43% and DCGO's 19.99%. Such benchmarking helps identify whether Biodesix Inc is trading at a premium or discount relative to its financial performance.
